mRNA Cancer Vaccines Reach a Breakthrough — But 'Turbo Cancer' Misinformation Threatens Uptake

Moderna and Merck reported on Aug. 19, 2026, that a personalized mRNA vaccine, intismeran autogene , reduced melanoma recurrence when combined with Keytruda — the first late-stage success for an mRNA cancer vac...



























